心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

冠心病合理用药指南(第2版)

2018-03-01 国家卫生计生委合理用药专家委员会 《中国医学前沿杂志(电子版)》

冠心病

2018年3月1日，由国家卫生计生委合理用 药专家委员会和中国药师协会组成指南修订联合委 员会，经 3 次联合会议讨论后最终确定了指南修订 的总体原则及新指南拟回答的核心问题。

中文标题：

冠心病合理用药指南(第2版)

发布机构：

国家卫生计生委合理用药专家委员会

发布日期：

2018-03-01

简要介绍：

2018年3月1日，由国家卫生计生委合理用 药专家委员会和中国药师协会组成指南修订联合委 员会，经 3 次联合会议讨论后最终确定了指南修订 的总体原则及新指南拟回答的核心问题。指南工作 组针对这些核心问题制定了具体的文献检索和评价 策略，综合评价、筛选出相关文献。

相关资料下载：
[AttachmentFileName(sort=1, fileName=_冠心病合理用药指南(第2版).pdf)] GetToolGuiderByIdResponse(projectId=1, id=9d70f1c00216e3cd, title=冠心病合理用药指南(第2版), enTitle=, guiderFrom=《中国医学前沿杂志(电子版)》, authorId=0, author=, summary=2018年3月1日，由国家卫生计生委合理用 药专家委员会和中国药师协会组成指南修订联合委 员会，经 3 次联合会议讨论后最终确定了指南修订 的总体原则及新指南拟回答的核心问题。, cover=https://img.medsci.cn/2021829/1630250153722_5579292.png, journalId=0, articlesId=null, associationId=1325, associationName=国家卫生计生委合理用药专家委员会, associationIntro=, copyright=0, guiderPublishedTime=Thu Mar 01 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div class="page" title="Page 1"> <div class="layoutArea"> <div class="column"> <p>2018年3月1日，由国家卫生计生委合理用 药专家委员会和中国药师协会组成指南修订联合委 员会，经 3 次联合会议讨论后最终确定了指南修订 的总体原则及新指南拟回答的核心问题。指南工作 组针对这些核心问题制定了具体的文献检索和评价 策略，综合评价、筛选出相关文献。</p> </div> </div> </div>, tagList=[TagDto(tagId=703, tagName=冠心病)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=703, guiderKeyword=冠心病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4262, appHits=916, showAppHits=0, pcHits=646, showPcHits=3335, likes=6, shares=114, comments=29, approvalStatus=1, publishedTime=Mon Aug 30 09:48:22 CST 2021, publishedTimeString=2018-03-01, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Sun Aug 29 23:16:01 CST 2021, updatedBy=1614372, updatedName=MedSciZeng, updatedTime=Sat Jan 06 11:25:39 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=_冠心病合理用药指南(第2版).pdf)])
_冠心病合理用药指南(第2版).pdf
下载请点击：
评论区 (23)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2094796, encodeId=fdd62094e9611, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=198f5456588, createdName=ms3000000190198551, createdTime=Wed Oct 19 19:50:32 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226948, encodeId=091e12269485a, content=学习了，很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210920/cc1287d895a346908d9358058cdb61ff/5ef3f7950426411ea0c9966d76a74064.jpg, createdBy=1d315559103, createdName=ms6000000225486324, createdTime=Fri Jun 17 01:58:43 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199635, encodeId=10e4119963541, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dff1956483, createdName=1e1275afm36(暂无匿称), createdTime=Sat Mar 05 13:06:38 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195774, encodeId=79a41195e74c0, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18034000901, createdName=139fe8b3m05暂无昵称, createdTime=Mon Feb 21 17:32:04 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187290, encodeId=5a23118e29023, content=好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dc96478592, createdName=ms2000001716855301, createdTime=Sat Jan 22 21:33:56 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2022-10-19 ms3000000190198551

    学习学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2094796, encodeId=fdd62094e9611, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=198f5456588, createdName=ms3000000190198551, createdTime=Wed Oct 19 19:50:32 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226948, encodeId=091e12269485a, content=学习了，很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210920/cc1287d895a346908d9358058cdb61ff/5ef3f7950426411ea0c9966d76a74064.jpg, createdBy=1d315559103, createdName=ms6000000225486324, createdTime=Fri Jun 17 01:58:43 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199635, encodeId=10e4119963541, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dff1956483, createdName=1e1275afm36(暂无匿称), createdTime=Sat Mar 05 13:06:38 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195774, encodeId=79a41195e74c0, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18034000901, createdName=139fe8b3m05暂无昵称, createdTime=Mon Feb 21 17:32:04 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187290, encodeId=5a23118e29023, content=好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dc96478592, createdName=ms2000001716855301, createdTime=Sat Jan 22 21:33:56 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2022-06-17 ms6000000225486324

    学习了，很好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2094796, encodeId=fdd62094e9611, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=198f5456588, createdName=ms3000000190198551, createdTime=Wed Oct 19 19:50:32 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226948, encodeId=091e12269485a, content=学习了，很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210920/cc1287d895a346908d9358058cdb61ff/5ef3f7950426411ea0c9966d76a74064.jpg, createdBy=1d315559103, createdName=ms6000000225486324, createdTime=Fri Jun 17 01:58:43 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199635, encodeId=10e4119963541, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dff1956483, createdName=1e1275afm36(暂无匿称), createdTime=Sat Mar 05 13:06:38 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195774, encodeId=79a41195e74c0, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18034000901, createdName=139fe8b3m05暂无昵称, createdTime=Mon Feb 21 17:32:04 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187290, encodeId=5a23118e29023, content=好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dc96478592, createdName=ms2000001716855301, createdTime=Sat Jan 22 21:33:56 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2022-03-05 1e1275afm36(暂无匿称)

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2094796, encodeId=fdd62094e9611, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=198f5456588, createdName=ms3000000190198551, createdTime=Wed Oct 19 19:50:32 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226948, encodeId=091e12269485a, content=学习了，很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210920/cc1287d895a346908d9358058cdb61ff/5ef3f7950426411ea0c9966d76a74064.jpg, createdBy=1d315559103, createdName=ms6000000225486324, createdTime=Fri Jun 17 01:58:43 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199635, encodeId=10e4119963541, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dff1956483, createdName=1e1275afm36(暂无匿称), createdTime=Sat Mar 05 13:06:38 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195774, encodeId=79a41195e74c0, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18034000901, createdName=139fe8b3m05暂无昵称, createdTime=Mon Feb 21 17:32:04 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187290, encodeId=5a23118e29023, content=好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dc96478592, createdName=ms2000001716855301, createdTime=Sat Jan 22 21:33:56 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2022-02-21 139fe8b3m05暂无昵称

    好

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2094796, encodeId=fdd62094e9611, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=198f5456588, createdName=ms3000000190198551, createdTime=Wed Oct 19 19:50:32 CST 2022, time=2022-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226948, encodeId=091e12269485a, content=学习了，很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210920/cc1287d895a346908d9358058cdb61ff/5ef3f7950426411ea0c9966d76a74064.jpg, createdBy=1d315559103, createdName=ms6000000225486324, createdTime=Fri Jun 17 01:58:43 CST 2022, time=2022-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199635, encodeId=10e4119963541, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dff1956483, createdName=1e1275afm36(暂无匿称), createdTime=Sat Mar 05 13:06:38 CST 2022, time=2022-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1195774, encodeId=79a41195e74c0, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=18034000901, createdName=139fe8b3m05暂无昵称, createdTime=Mon Feb 21 17:32:04 CST 2022, time=2022-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1187290, encodeId=5a23118e29023, content=好的, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9dc96478592, createdName=ms2000001716855301, createdTime=Sat Jan 22 21:33:56 CST 2022, time=2022-01-22, status=1, ipAttribution=)]
    2022-01-22 ms2000001716855301

    好的

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

冠心病双联抗血小板治疗中国专家共识

中华医学会心血管病学分会(Chinese Society of Cardiology) · 2021-05-28

2021 ACR适宜性标准：无症状冠心病高危患者

美国放射学会(ACR,American College of Radiology) · 2021-05-18

中成药治疗冠心病临床应用指南（2020年）

暂未更新 · 2021-05-15

2021 SCCT专家共识文件：心血管CT在冠心病职业健康评估中的作用

美国心血管计算机断层扫描学会(SCCT,Society of Cardiovascular Computed Tomography) · 2021-04-20

冠心病心脏康复基层合理用药指南

中华医学会(CMA,Chinese Medical Association) · 2021-03-25

稳定性冠心病基层诊疗指南（实践版·2020）

中华医学会(CMA,Chinese Medical Association) · 2021-03-20

拓展阅读

2016 ACC/AHA指南：冠心病患者双抗治疗持续时间（更新）

美国心脏病学会(ACC,American College of Cardiology) · 2016-03-30

2015 冠心病患者运动治疗中国专家共识

中华医学会心血管病学分会(Chinese Society of Cardiology) · 2016-04-27

2015 AHA/ACC/ASH 冠心病患者高血压治疗的科学声明

美国心脏病学会(ACC,American College of Cardiology) · 2015-03-30

2016 冠心病合理用药指南

暂未更新 · 2016-06-30

2016 高龄老年冠心病诊治中国专家共识

中华医学会老年医学分会 · 2016-07-30

冠心病血瘀证诊断标准

暂未更新 · 2016-10-30